<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20688">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837575</url>
  </required_header>
  <id_info>
    <org_study_id>HSV2-201</org_study_id>
    <nct_id>NCT02837575</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine</brief_title>
  <acronym>HSV-2</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety and efficacy of a therapeutic DNA
      vaccine in adults with symptomatic herpes simplex virus type 2 (i.e., genital herpes).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and efficacy of 4 doses of VCL-HB01, a therapeutic HSV plasmid DNA
      vaccine formulated with VaxfectinÂ® in HSV-2-seropositive adults with a reported history of
      symptomatic genital herpes for at least one year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion recurrences</measure>
    <time_frame>Up to Day 450</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to Day 450</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first recurrence</measure>
    <time_frame>Up to Day 450</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects recurrence-free</measure>
    <time_frame>Up to Day 450</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Herpes Genitalis</condition>
  <arm_group>
    <arm_group_label>VCL-HB01, 1-mL dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phosphate-buffered saline, 1-mL dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBS, 1-mL dose by intramuscular injection once every 28 days for 4 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VCL-HB01</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>VCL-HB01, 1-mL dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phosphate-buffered saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Phosphate-buffered saline, 1-mL dose</arm_group_label>
    <other_name>PBS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HSV-2 seropositive

          -  A minimum of 1 year of reported history of genital herpes with recurrences.

        Exclusion Criteria:

          -  History of receiving an investigational HSV vaccine

          -  Chronic illness for which a subject's immune system is suspected to be impaired or
             altered, such as cancer, autoimmune conditions, or diabetes

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mammen P Mammen, MD, FIDSA</last_name>
    <role>Study Director</role>
    <affiliation>Vical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Vaccine Research Clinic at University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-2050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santorra King</last_name>
      <phone>205-996-4099</phone>
      <email>santorraking@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Kerr</last_name>
      <phone>619-521-2841</phone>
      <email>kkerr@mccresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>QPS Broward Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Garcia</last_name>
      <phone>954-374-1150</phone>
      <phone_ext>114</phone_ext>
      <email>barbara.garcia@qps.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>QPS Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Arguelles, LPN, CCRC</last_name>
      <phone>305-598-3125</phone>
      <email>Meredith.Anguelles@qps.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Ackerman, CCRC, CCRP</last_name>
      <phone>561-478-3177</phone>
      <email>jackerman@cctllc.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Harden</last_name>
      <phone>312-413-5897</phone>
      <email>ginaha@uic.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Infectious Disease Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Johnson</last_name>
      <phone>317-278-2945</phone>
      <email>johnpaul@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Burton</last_name>
      <phone>316-689-6626</phone>
      <email>mburton@heartlandresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Hudson</last_name>
      <phone>859-977-7142</phone>
      <email>thudson@ckrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrollment Services</last_name>
      <phone>816-943-0770</phone>
      <email>es@cprkc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Lovett</last_name>
      <phone>585-288-0890</phone>
      <email>volunteer@rcrclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina (UNC) Institute of Global Health and Infectious Diseases</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Hoffman</last_name>
      <phone>919-843-0720</phone>
      <email>erin_hoffman@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwen Mooney</last_name>
      <phone>615-329-0197</phone>
      <email>gwen@cranashville.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine - Division of Infectious Diseases</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jane Tinnes</last_name>
      <phone>801-585-2254</phone>
      <email>maryjane.tinnes@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Drummond</last_name>
      <phone>206-520-4340</phone>
      <email>mjd520@u.washington.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>July 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSV-2</keyword>
  <keyword>Genital Herpes</keyword>
  <keyword>Herpes</keyword>
  <keyword>Herpes Simplex Virus, Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
